How We Incorporate Venetoclax in Treatment Regimens for Acute Myeloid Leukemia

Venetoclax has transformed the therapeutic landscape of acute myeloid leukemia (AML). Hypomethylating agents with venetoclax (HMA-VEN) have significantly improved outcomes and have become the standard therapy for older/unfit patients with newly diagnosed AML and are comparable to intensive chemother...

Descripción completa

Detalles Bibliográficos
Autores principales: Maiti, Abhishek, Konopleva, Marina Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Review Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8785772/
https://www.ncbi.nlm.nih.gov/pubmed/35072368
http://dx.doi.org/10.1097/PPO.0000000000000567

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8785772/
https://www.ncbi.nlm.nih.gov/pubmed/35072368
http://dx.doi.org/10.1097/PPO.0000000000000567

Ejemplares similares